Year-end Sale % OFF 
Abstract
Over the past few years, Candida auris has emerged as a deadly nosocomial multi-drug-resistant (MDR) pathogen around the globe [ [1] Jeffery-Smith A. Taori S.K. Schelenz S. Jeffery K. Johnson E.M. Borman A. et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018; 31: e00029-17 PubMed Google Scholar ]. There is a danger of C. auris transmission in hospitals of developing countries due to their limited facilities for fungal identification and antifungal susceptibility testing [ [2] Schwartz I.S. Hammond G.W. First reported case of multidrug-resistant Candida auris in Canada. Can Commun Dis Rep. 2017; 43: 150 Crossref PubMed Google Scholar ]. Excessive use of fluconazole empirically has made a shift of invasive candida infections from albicans to non-albicans Candida spp. It has also contributed to the emergence of MDR yeasts in hospital environments [ [3] Deorukhkar S.C. Saini S. Mathew S. Non-albicans Candida infection: an emerging threat. Interdiscip Perspect Infect Dis. 2014; 2014: 615958 Crossref PubMed Scopus (121) Google Scholar ].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
